

INTEGRA LIFESCIENCES HOLDINGS CORP  
Form 424B7  
March 13, 2008

File pursuant to Rule 424(b)(7)  
Registration No. 333-146185

PROSPECTUS SUPPLEMENT NO. 2  
(To prospectus dated September 19, 2007)

2,490,131 Shares

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Common Stock

This prospectus supplement no. 2, which supplements the prospectus dated September 19, 2007 and filed by us on September 20, 2007 (as amended by prospectus supplement no. 1 dated December 14, 2007), relates to the resale from time to time by selling stockholders of the shares of common stock that may be issued to them upon the conversion of our 2.75% Senior Convertible Notes due 2010.

You should read this prospectus supplement no. 2 in conjunction with the related prospectus and prospectus supplement no. 1, which should be delivered in conjunction with this prospectus supplement no. 2. This prospectus supplement no. 2 is not complete without, and may not be delivered or used except in conjunction with the prospectus, including prospectus supplement no. 1 and any amendments or other supplements to the prospectus. This prospectus supplement no. 2 is qualified by reference to the prospectus and prospectus supplement no. 1, except to the extent that the information provided by this prospectus supplement no. 2 supersedes information contained in the prospectus and prospectus supplement no. 1.

You should read and rely only on the information contained in this prospectus supplement no. 2 and the related prospectus and prospectus supplement no. 1, together with additional information described on page 34 of the related prospectus under the heading "Where You Can Find More Information and Incorporation by Reference." Neither we nor the selling stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the selling stockholders are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained or incorporated by reference in this prospectus supplement no. 2 or the related prospectus and prospectus supplement no. 1 is accurate only as of the dates of the documents containing the information.

Investing in our common stock involves risks. See "Risk Factors" beginning on page 5 of the related prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement no. 2 and the related prospectus and prospectus supplement no. 1. Any representation to the contrary is a criminal offense.

THIS PROSPECTUS SUPPLEMENT NO. 2 IS DATED MARCH 13, 2008.

## SELLING STOCKHOLDERS

The information appearing in the table below with respect to the selling stockholders named therein supplements and supersedes the information with respect to such selling stockholders in the table appearing under the heading "Selling Stockholders" in the related prospectus dated September 19, 2007 and filed on September 20, 2007 and prospectus supplement no. 1. The information is based solely on information provided to us by or on behalf of the selling stockholders on or prior to March 12, 2008 in Selling Securityholder Notices and Questionnaires.

The number of shares of our common stock issuable upon the conversion of the notes shown in the table below assumes conversion of the full amount of notes held by each selling stockholder at the initial conversion rate of 15.0917 shares of our common stock per \$1,000 principal amount of notes and a cash payment in lieu of any fractional share, which rate is subject to adjustment upon the occurrence of certain events. Accordingly, the number of shares of our common stock issued upon the conversion of the notes may increase or decrease from time to time. The selling stockholders may offer all, some or none of the shares of our common stock that we may issue upon the conversion of the notes. Therefore, we cannot estimate the number of shares of our common stock that will be held by the selling stockholders upon consummation of any of these sales. The number of shares of our common stock owned by the other selling stockholders or any future transferee from any such holder assumes that they do not beneficially own any shares of common stock other than the common stock that we may issue to them upon the conversion of the notes. In addition, the selling stockholders identified below may have acquired, sold, transferred or otherwise disposed of, in transactions exempt from the registration requirements of the Securities Act, all or a portion of their notes or shares of our common stock since the date on which they provided the information regarding their notes and therefore the aggregate number of shares set forth in the table below may exceed the number of shares actually issuable upon conversion of the notes.

Based upon information provided by the selling stockholders, none of the selling stockholders or their affiliates has, or within the past three years has had, any material relationship with us or any of our predecessors or affiliates, except as disclosed below.

Name of Selling Stockholder	Principal Amount of Notes Owned Prior to Offering (in U.S. dollars)	Number of Shares Beneficially Owned Prior to Offering (1)	Number of Shares Being Offered
Advent Convertible Arbitrage Master	8,535,000	128,807	128,807
Advent Enhanced Phoenix	4,285,000	64,667	64,667
B.C. McCabe Foundation	150,000	2,263	2,263
Commissioners of the Land Office	2,010,000	30,334	30,334
dbx-Convertible Arbitrage 12 Fund c/o			
Quattro Global Capital, LLC	376,000	5,674	5,674
Florida Light and Power	912,000	13,763	13,763

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 424B7

Forest Global Convertible Master Fund, L.P.	2,268,000	34,227	34,227
Forest Multi-Strategy Master Fund SPC, on behalf of its Multi-Strategy Segregated Portfolio	80,000	1,207	1,207
Governing Board Employees Benefit Plan of the City of Detroit	12,000	181	181
Healthcare Georgia Foundation	58,000	875	875
HFR CA Global Opportunity Master Trust	593,000	8,949	8,949
HFR CA Op Master Trust	119,000	1,795	1,795
HFR RVA Select Performance Master Trust	245,000	3,697	3,697
Institutional Benchmark Series Limited Institutional Benchmark Series (Master Feeder) Limited in respect of Electra Series c/o Quattro Global Capital, LLC	897,000	13,537	13,537
Intl. Truck & Engine Corp. Non Contributory Retirement Plan Trust	1,316,000	19,860	19,860
Intl. Truck & Engine Corp. Retirement Plan for Salaried Employees Trust	925,000	13,959	13,959
KeySpan Insurance Company	450,000	6,791	6,791
KeySpan Foundation	225,000	3,395	3,395
LLT Limited	85,000	1,282	1,282
Lord Abbett Investment Trust -- LA Convertible Fund	266,000	4,014	4,014
Lyxor/Forest Fund Limited	5,370,000	81,042	81,042
Lyxor Master Trust Fund	4,048,000	61,091	61,091
Lyxor / Quattro Fund Limited c/o Quattro Global Capital, LLC	126,000	1,901	1,901
National Fuel & Gas Company Retirement Plan	150,000	2,263	2,263
NYC Teachers' Variable Annuity Fund Pension, Hospitalization Benefit Plan of the Electrical Ind Plan	700,000	10,564	10,564
Philadelphia Board of Pensions	2,050,000	30,937	30,937
Quattro Fund Ltd.	800,000	12,073	12,073
Quattro Multistrategy Masterfund LP	875,000	13,205	13,205
Raytheon Phoenix	7,144,000	107,815	107,815
Sage Capital Management, LLC	564,000	8,511	8,511
SCI Cemetery Merchandise Common Trust	756,000	11,409	11,409
SCI Pre-Need Common Trust Fund	1,500,000	22,637	22,637
Seattle City Employee Retirement System	160,000	2,414	2,414
Teacher Retirement System of the City of New York	80,000	1,207	1,207
Tenor Opportunity Master Fund, Ltd.	85,000	1,282	1,282
Total Fina Elf Finance USA, Inc.	1,134,000	17,113	17,113
Vermont Mutual Insurance Company	35,000,000	528,209	528,209
	375,000	5,659	5,659
	200,000	3,018	3,018

\* Less than 1%.

(1) Certain of the selling stockholders listed in this table may also own or be deemed to own shares of the Company's common stock issuable upon conversion of the 2008 notes and/or the 2012 notes.

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 424B7

- (2) The beneficial ownership in this column assumes that the selling stockholder sells all of the shares offered by this prospectus that are beneficially owned by the selling stockholder and that prior to the sale of such shares the selling stockholder does not acquire additional shares or dispose of shares beneficially owned by the stockholder that are not being offered pursuant to this prospectus.
  
- (3) The percentage of outstanding shares is based on 26,454,967 shares of common stock outstanding as of March 6, 2008.